The Efficacy of Gabapentin Versus Trospium Chloride for Prevention of a Catheter-related Bladder Discomfort (CRBD) Inside the Intensive Care Unit (ICU): a Prospective, Randomized,Comparative Clinical Study

Catheter-related bladder discomfort (CRBD) is a frequent complaint after urinary bladder catheterization which is commonly done in the perioperative period. CRBD shows similar symptoms to overactive bladder (OAB); so, drugs used for the management of OAB could influence symptoms of CRBD. Trospium chloride and gabapentin are effective in managing patient with OAB even the resistant cases. We will evaluate and compare the efficacy of both oral trospium and gabapentin on prevention of CRBD in the postoperative period in the ICU in in patients undergoing spinal surgery and requiring intraoperative catheterization of the urinary bladder.

Start Date24 Feb 2024

Sponsor / Collaborator

Ain Shams University

NCT05658874 / RecruitingPhase 3IIT

A Multidisciplinary, Multimodal Bundled Care Approach to Chronic Pelvic Pain

The goal of this clinical trial is to compare two different treatment patterns in patients with chronic bladder pain. The main questions the investigators are seeking to answer is if bladder pain improves before and after treatment using a painful bladder scale. The participant will have 5 visits to evaluate your symptoms with questionnaires, at least one procedural visit, and must participate in physical therapy and some kind of behavioral health therapy. This study will assess participant response to a bundled-care approach to chronic bladder pain both pre-and post intervention as well as compared to a group of participants receiving typical care.

Start Date01 Dec 2022

Sponsor / Collaborator-

IRCT20160606028304N2 / CompletedPhase 4

Efficacy of Solifenacin and trospium chloride on neurogenic bladder after stroke: a multicentric three arms placebo-controlled trial

Start Date01 Jul 2021

Sponsor / Collaborator

Tabriz University of Medical Sciences

100 Clinical Results associated with Trospium Chloride

100 Translational Medicine associated with Trospium Chloride

100 Patents (Medical) associated with Trospium Chloride

325

Literatures (Medical) associated with Trospium Chloride

01 Jan 2024·Lancet (London, England)Q1 · MEDICINE

Efficacy and safety of the muscarinic receptor agonist KarXT (xanomeline–trospium) in schizophrenia (EMERGENT-2) in the USA: results from a randomised, double-blind, placebo-controlled, flexible-dose phase 3 trial

Q1 · MEDICINE

Article

Author: Correll, Christoph U ; Paul, Steven M ; Zhu, Haiyuan ; Sawchak, Sharon ; Kaul, Inder ; Brannan, Stephen K ; Miller, Andrew C ; Kakar, Rishi ; Breier, Alan

BACKGROUND:

New treatments with new mechanisms are urgently needed for people with schizophrenia. Xanomeline is a dual M₁ and M₄-preferring muscarinic receptor agonist that does not block D₂ dopamine receptors, unlike all currently approved treatments for schizophrenia. Xanomeline-trospium (KarXT) combines xanomeline with the peripherally restricted muscarinic receptor antagonist trospium chloride with the goal of ameliorating xanomeline-related adverse events associated with peripheral muscarinic receptors. The EMERGENT-2 trial aimed to assess the efficacy and safety of KarXT in people with schizophrenia experiencing acute psychosis.

METHODS:

EMERGENT-2 was a randomised, double-blind, placebo-controlled, flexible-dose, 5-week, inpatient, phase 3 trial in people with schizophrenia. Participants were adults aged 18-65 years with a diagnosis of schizophrenia who had a recent worsening of psychosis warranting hospital admission, a Positive and Negative Syndrome Scale (PANSS) score of 80 or higher, and a Clinical Global Impression-Severity score of 4 or higher. The participants were recruited from 22 inpatient sites in the USA, and were randomly assigned (1:1) to KarXT or placebo twice per day. Participants randomly assigned to KarXT received 50 mg xanomeline and 20 mg trospium twice per day for the first 2 days and then 100 mg xanomeline and 20 mg trospium twice per day for days 3-7. Beginning on day 8, KarXT dosing was flexible with an optional increase to 125 mg xanomeline and 30 mg trospium twice per day and the option to return to 100 mg xanomeline and 20 mg trospium based on tolerability. The primary endpoint was change from baseline to week 5 in PANSS total score. Efficacy analyses used the modified intention-to-treat population (all randomly assigned participants who received at least one trial medication dose and had at least one post-baseline PANSS assessment). Least squares mean change from baseline, SE, and least squares mean difference between the KarXT and placebo groups at week 5, along with the 95% CI and two-sided p values were calculated for the primary and secondary continuous efficacy endpoints. Safety analyses included all participants receiving at least one trial medication dose and used descriptive statistics. This trial is registered with ClinicalTrials.gov (NCT04659161).

FINDINGS:

From Dec 16, 2020, to April 13, 2022, of 407 people who were screened, 252 participants meeting enrolment criteria were randomly assigned to the KarXT (n=126) or placebo (n=126). Baseline PANSS total scores were 98·3 (KarXT; n=126) and 97·9 (placebo; n=125). The trial met the primary endpoint with a mean change from baseline to week 5 in PANSS total score that favoured KarXT (-21·2 points, SE 1·7) versus placebo (-11·6 points, 1·6; least squares mean difference -9·6; 95% CI -13·9 to -5·2; p<0·0001, Cohen's d effect size=0·61). All secondary endpoints were also met, and favoured KarXT versus placebo (p<0·05). The most common adverse events with KarXT versus placebo were constipation (27 [21%] vs 13 [10%]), dyspepsia (24 [19%] vs 10 [8%]), headache (17 [14%] vs 15 [12%]), nausea (24 [19%] vs seven [6%]), vomiting (18 [14%] vs one [1%]), hypertension (12 [10%] vs one [1%]), dizziness (11 [9%] vs four [3%]), gastro-oesophageal reflux disease (eight [6%] vs zero [0%]), and diarrhoea (seven [6%] vs four [3%]). Treatment-emergent adverse event rates of extrapyramidal motor symptoms (KarXT, zero [0%] vs placebo, zero [0%]), akathisia (one [1%] vs one [1%]), weight gain (zero [0%] vs one [1%]), and somnolence (six [5%] vs five [4%]) were similar between the KarXT and placebo groups, as were adverse event-related discontinuation rates (nine [7%] vs seven [6%]).

INTERPRETATION:

In the EMERGENT-2 trial, KarXT was effective in reducing positive and negative symptoms and was generally well tolerated. These results support the potential for KarXT to represent a new class of effective and well tolerated antipsychotic medicines based on activating muscarinic receptors, not the D₂ dopamine receptor-blocking mechanism of all current antipsychotic medications. Results from additional trials, including the identical EMERGENT-3 trial and the 52-week, open-label EMERGENT-4 and EMERGENT-5 trials, will provide additional information on the efficacy and safety of KarXT in people with schizophrenia.

FUNDING:

Karuna Therapeutics.

02 Dec 2023·Expert opinion on therapeutic patents

The patent review of the biological activity of tropane containing compounds

Review

Author: Farghaly, Thoraya A ; Masaret, Ghada S ; Abdulwahab, Hanan Gaber

INTRODUCTION:

Tropane-derived medications have historically played a substantial role in pharmacotherapy. Both natural and synthetic derivatives of tropane find application in addressing diverse medical conditions. Prominent examples of tropane-based drugs include hyoscine butylbromide, recognized for its antispasmodic properties, atropine, employed as a mydriatic, maraviroc, known for its antiviral effects. trospium chloride, utilized as a spasmolytic for overactive bladder, and ipratropium, a bronchodilator.

AREAS COVERED:

We compiled patents pertaining to the biological activity of substances containing tropane up to the year 2023 and categorized them according to the specific type of biological activity they exhibit. ScienceFinder, ScienceDirect, and Patent Guru were used to search for scientific articles and patent literature up to 2023.

EXPERT OPINION:

Pharmaceutical researchers in academic and industrial settings have shown considerable interest in tropane derivatives. Despite this, there remains a substantial amount of work to be undertaken. A focused approach is warranted for the exploration and advancement of both natural and synthetic bioactive molecules containing tropane, facilitated through collaborative efforts between academia and industry. Leveraging contemporary techniques and technologies in medicinal and synthetic chemistry, including high throughput screening, drug repurposing,and biotechnological engineering, holds the potential to unveil novel possibilities and accelerate the drug discovery process for innovative tropane-based pharmaceuticals.

01 Sep 2023·Pharmaceutical research

Is the One-Compartment Model with First Order Absorption a Useful Approximation?

Article

Author: Weiss, Michael

PURPOSE:

The one-compartment model with first order absorption (ka1C) has been extensively used to fit oral data. But when the disposition parameters of the drug are not available, the bias in the parameter estimates remains unclear. In this paper, the effect of potential misspecification of the area under the curve (AUC) and the mean absorption time (MAT) was evaluated for three relatively slowly absorbed drugs/formulations.

METHODS:

Assuming a three-compartment disposition model with an input (absorption) rate described as a sum of two inverse Gaussian functions (2IG3C) as the true model, the deviations of AUC and MAT estimated with simpler models were analyzed. Simpler models, as the ka1C model (Bateman function), the one-compartment model with IG input function (IG1C) and the gamma density function were fitted to the oral data alone, and compared to the fits obtained with the 2IG3C model which also uses the 3C disposition parameters of the drug. Data from pharmacokinetic studies of trospium, propiverine and ketamine in healthy volunteers were analyzed using a population approach.

RESULTS:

The Bateman function (ka1C) allowed a robust estimation of the population mean AUC, but the individual estimates were highly biased. It failed in evaluating MAT. The simple alternative models did not improve the situation.

CONCLUSIONS:

The Bateman function appears to be useful for estimating the population mean value of AUC after oral administration. The results reemphasize the fact that insight into the absorption process can be only gained when also intravenous reference data are available.

News (Medical) associated with Trospium Chloride

23 May 2024

·www.biospace.com

Bristol Myers Squibb to Present Data at the 2024 American Society of Clinical Psychopharmacology Annual Meeting

Consistent with short-term studies, KarXT was not associated with clinically meaningful changes in movement disorder scale scores and a low incidence rate of extrapyramidal symptoms was reported over long-term trials in adults with schizophrenia In-trial qualitative interviews found that the majority of participants treated with KarXT in the long-term EMERGENT-5 trial perceived improvements in positive, negative and cognitive symptoms of schizophrenia PRINCETON, N.J.--(BUSINESS WIRE)-- Bristol Myers Squibb Company (NYSE: BMY) today announced the presentation of data at the 2024 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting, taking place May 28-31, 2024 in Miami, FL. “The presentation of additional data from the EMERGENT program continues to illustrate the potential of KarXT as a novel treatment for schizophrenia, with its differentiated mechanism of action and safety and efficacy profile,” said Alyssa Johnsen, MD, PhD, senior vice president and head of clinical development, Immunology, Cardiovascular and Neuroscience, Bristol Myers Squibb. “The impact of KarXT for patients and their care partners is promising, and we look forward to continuing our conversations with the U.S. Food & Drug Administration this year.” Research to be presented at the meeting continues to demonstrate the potential of KarXT as a differentiated treatment option for adults living with schizophrenia. Notable data poster presentations include: Low Long-Term Risk of Extrapyramidal Symptoms (EPS) with Muscarinic Agonist KarXT (Xanomeline and Trospium) (W86) Among pooled interim data from the Phase 3 outpatient, 52-week, open-label EMERGENT-4 and EMERGENT-5 studies, the incidence of extrapyramidal symptoms (EPS) adverse events (AEs) deemed to be treatment-related was 1% and the most commonly reported treatment-related EPS AE was akathisia (0.6%). KarXT was not associated with clinically meaningful changes from baseline in movement disorder scale scores on the Simpson-Angus Scale (SAS), Barnes Akathisia Rating Scale (BARS), and Abnormal Involuntary Movement Scale (AIMS) over short or long-term studies. Assessing Participant Experience with KarXT Treatment Using In-Trial Qualitative Interviews: Initial Findings from a Long-Term Phase 3 Trial in Schizophrenia (W24) In the Phase 3 outpatient, 52-week, open-label EMERGENT-5 trial evaluating the safety, tolerability and efficacy of KarXT in adults with schizophrenia, in-trial interviews were conducted with participants to provide qualitative insights to characterize their experience during the trial to better understand changes in symptoms and define meaningful treatment. Initial findings showed participants perceived an improvement in positive, negative, and cognitive symptoms of schizophrenia since initiating KarXT. Complete abstracts may be accessed online here, and a full overview of abstracts to be presented at ASCP by BMS can be found below. Abstract Title Primary Author Type/# Session Title Time (ET) Wednesday, May 29, 2024 Assessing Participant Experience with KarXT Treatment Using In-Trial Qualitative Interviews: Initial Findings from a Long-Term Phase 3 Trial in Schizophrenia Horan, W. Poster W24 Poster Session I 11:15 AM – 1:15 PM Characterizing the Safety Pro KarXT Relative to Anticipated D2-Dopamine-based Antipsychotic Medications in FAERS Ramsay, I. Poster W52 Low Long-Term Risk of EPS with Muscarinic Agonist KarXT (Xanomeline and Trospium) Novak, K. Poster W86 Thursday, May 30, 2024 KarXT (Xanomeline and Trospium) for the Treatment of Schizophrenia: Number Needed to Treat, Number Needed to Harm, and likelihood to Be Helped or Harmed Citrome, L. Poster T58 Poster Session II 12:30 PM - 2:15 PM Responses to KarXT in Short-Term Placebo-Controlled Trials in Schizophrenia Ramsay, I. Poster T76 Measurement of Positive and Negative Symptoms Through Speech Analysis from PANSS Interview Recordings in Patients with Schizophrenia Abbas, A. Poster T78 About KarXT KarXT (xanomeline-trospium) is an investigational muscarinic antipsychotic in development for the treatment of schizophrenia and psychosis related to Alzheimer’s disease. Through its novel mechanism of action, KarXT acts as a dual M1/M4 muscarinic acetylcholine receptor agonist in the central nervous system, which is thought to improve positive, negative, and cognitive symptoms of schizophrenia. Unlike existing treatments, KarXT does not directly block dopamine receptors, representing a potential new approach to treating schizophrenia. About Schizophrenia Schizophrenia is a persistent and often disabling mental illness impacting how a person thinks, feels, and behaves, and affects nearly 24 million people worldwide, including 2.8 million people in the U.S. It is characterized by three symptom domains: positive symptoms (hallucinations and delusions), negative symptoms (difficulty enjoying life and withdrawal from others), and cognitive impairment (deficits in memory, concentration, and decision-making). In part due to limitations with current treatments, people living with schizophrenia often struggle to maintain employment, live independently, and manage relationships. While current treatments can be effective in managing select symptoms, approximately 30% of people do not respond to therapy, with an additional 50% experiencing only a partial improvement in symptoms or unacceptable side effects. Bristol Myers Squibb: Delivering Breakthrough Science for Meaningful Interventions in Neuroscience Neurological conditions represent some of the greatest challenges of our time because of their impact on society, including patients, caregivers, families and healthcare systems. At Bristol Myers Squibb, we are committed to advancing our robust pipeline of potential medicines for neurological disorders with the goal of modifying disease and improving quality of life. Leveraging genetics, biomarkers and predictive sciences, we target key pathways involved in the initiation and progression of neurological diseases to develop therapies with the potential to optimize patient outcomes. About Bristol Myers Squibb Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information about Bristol Myers Squibb, visit us at BMS.com or follow us on LinkedIn, Twitter, YouTube, Facebook and Instagram. Cautionary Statement Regarding Forward-Looking Statements This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 regarding, among other things, the research, development and commercialization of pharmaceutical products. All statements that are not statements of historical facts are, or may be deemed to be, forward-looking statements. Such forward-looking statements are based on current expectations and projections about our future financial results, goals, plans and objectives and involve inherent risks, assumptions and uncertainties, including internal or external factors that could delay, divert or change any of them in the next several years, that are difficult to predict, may be beyond our control and could cause our future financial results, goals, plans and objectives to differ materially from those expressed in, or implied by, the statements. These risks, assumptions, uncertainties and other factors include, among others, that future study results may not be consistent with the results to date, that KarXT may not receive regulatory approval for the indication described in this release in the currently anticipated timeline or at all, any marketing approvals, if granted, may have significant limitations on their use, and, if approved, whether KarXT for such indication described in this release will be commercially successful. No forward-looking statement can be guaranteed. Forward-looking statements in this press release should be evaluated together with the many risks and uncertainties that affect Bristol Myers Squibb’s business and market, particularly those identified in the cautionary statement and risk factors discussion in Bristol Myers Squibb’s Annual Report on Form 10-K for the year ended December 31, 2023, as updated by our subsequent Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and other filings with the Securities and Exchange Commission. The forward-looking statements included in this document are made only as of the date of this document and except as otherwise required by applicable law, Bristol Myers Squibb undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, changed circumstances or otherwise. corporatefinancial-news

Phase 3Clinical ResultASCO

20 May 2024

·www.biospace.com

Terran Biosciences Announces Development of TerXT, a Combination of Xanomeline and Trospium Prodrugs for the Treatment of Schizophrenia, and Intends to Pursue Accelerated 505(b)(2) Approval Pathway

MIAMI--(BUSINESS WIRE)-- Terran Biosciences Inc. ("Terran"), a biotech platform company developing therapeutics and technologies for patients with neuropsychiatric illnesses, has announced the development of TerXT, a combination of novel prodrugs of xanomeline and trospium designed to be long-acting treatments for schizophrenia. Terran has received notice of patent claims found to be allowable from the United States Patent and Trademark Office (USPTO) for the composition of matter for the world’s first prodrugs of xanomeline. To develop TerXT, Terran sought to overcome inherent pharmacokinetic and physical property limitations of the compounds xanomeline and trospium, such as poor colonic absorption and high aqueous solubility, by utilizing a novel prodrug strategy. These prodrugs were designed to enable fixed-dose combinations for once-daily oral administration (“TerXT”) and long-acting intramuscular injection with multi-month duration (“TerXT LAI”). These new forms could potentially allow Terran to pursue accelerated development and regulatory strategies such as the FDA 505(b)(2) approval pathway. Recent clinical trials of an oral, twice-daily, fixed-dose combination of xanomeline, a compound invented in the 1990s, and trospium, invented in the 1960s, have demonstrated safety and efficacy in treating schizophrenia. This combination has been submitted to the FDA for approval on the 505(b)(1) path and is currently undergoing FDA review, with a decision expected by September this year. If the FDA approves the xanomeline/trospium combination, Terran plans to pursue the rapid 505(b)(2) approval pathway for TerXT and TerXT LAI. This regulatory pathway could potentially enable Terran to use pharmacokinetic bridging studies and leverage existing safety and efficacy data from completed trials to bring Terran’s next-generation therapeutics to market approximately five years after the first xanomeline/trospium approval, helping to broaden access for patients, improve the use profile, and increase affordability. In order to successfully overcome the pharmacokinetic limitations of xanomeline and trospium, Terran assembled a team of the world’s experts in medicinal chemistry, resulting in over 10,000 new prodrugs designs. Terran’s PK modeling team developed a predictive model of both xanomeline and trospium across a vast spectrum of different formulation designs and release profiles to determine the optimal pharmacokinetic parameters and ratios. Terran utilized a team of 200 chemists to synthesize over 500 prodrugs, which then underwent preclinical testing, including 285 in vitro and 365 in vivo studies. “We’ve seen the prodrug approach significantly improve long-acting formulations of some of the most effective antipsychotics to date, including Aristada®, Haldol® Decanoate, and Invega Hafyera®, to the great benefit of patients,” said Sam Clark, MD, PhD, Terran’s founder and CEO, and inventor on the patent. “However, these improved forms were not developed until many years after the original compounds were first approved; in some cases, decades later. At Terran, we believe patients shouldn’t have to wait for the latest technology and we believe that our prodrugs of xanomeline and trospium will enable improvements in ease of use and quality of life on a much more rapid timescale than has historically been achieved.” ABOUT TERRAN BIOSCIENCES Terran Biosciences is a biotech platform company developing a portfolio of therapeutics and technologies for patients with neurological and psychiatric diseases. Terran has built a CNS-focused, tech-enabled drug development platform and is rapidly advancing a number of assets that include late-stage therapeutics for schizophrenia, an FDA-cleared neuroimaging software platform, and a drug design engine that has generated first-in-class and best-in-class psychedelic-based therapeutics and novel prodrugs optimized for patient use. Follow us on LinkedIn and X. For more information on TerXT visit

Clinical Study

08 Apr 2024

·www.pharmamanufacturing.com

BMS schizophrenia drug improves symptoms in phase 3 trial

Long-term treatment with Bristol Myers Squibb's experimental schizophrenia drug, KarXT, was associated with continued improvements in symptoms, according to new interim results from the phase 3 EMERGENT-4 trial. In the interim analysis, presented at the Annual Congress of the Schizophrenia International Research Society, KarXT was associated with significant improvement in symptoms of schizophrenia across all efficacy measures at 52 weeks. The analysis included 110 patients, with 29 patients having completed 52 weeks of treatment. At the end of the open-label extension, more than 75% of participants achieved >30% improvement in symptoms, with an average reduction of 33.3 points from baseline, as measured by the Positive and Negative Syndrome Scale total score. According to BMS, the drug also demonstrated a favorable impact on weight and long-term metabolic profile. The results are great news for BMS, having recently snatched up the promising treatment in late 2023 through its $14 billion acquisition of Karuna Therapeutics. KarXT is a potentially revolutionary schizophrenia treatment, marking the first major pharmacological innovation in the field in decades. The orally administered drug uniquely targets M1/M4 muscarinic receptors, diverging from traditional treatments by avoiding dopamine and serotonin pathways. This dual-action strategy seeks to exploit xanomeline's benefits while mitigating side effects with trospium, potentially introducing a unique treatment option for severe mental health conditions. KarXT currently has a PDUFA date of September 26, 2024.

Clinical ResultPhase 3Acquisition

100 Deals associated with Trospium Chloride

External Link

KEGG	Wiki	ATC	Drug Bank
D01103	Trospium Chloride	G04BD09	-

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Urinary Bladder, Overactive	FR	Allergan Ltd. (Ireland)	28 Jun 1999

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Pulmonary Disease, Chronic Obstructive	Phase 2	US	Endo Pharmaceuticals, Inc.	01 Apr 2007

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04090190 (CTgov)	Phase 4	Urinary Incontinence \| Urinary urgency \| Inflammation	20	Oxybutynin+Tolterodine+Trospium+Solifenacin+Fesoterodine	njpnijqcvm(hdvjqiapjh) = ultdhddcfe gaynbactfc (tcxeocmwcl, frlrebddpf - yujgxjqbxl) View more	-	03 Oct 2022
NCT03697252 (EMERGENT-1, Pubmed \| Br Dent J) Manual	Phase 2	Schizophrenia	182	xanomeline	uaqnuhgvym(smwxgtvesp) = rpjqokmrvo nbnsqwfcyg (jkmilzvbfu )	Positive	25 Feb 2021
				Placebo	uaqnuhgvym(smwxgtvesp) = avcngmxqqc nbnsqwfcyg (jkmilzvbfu )
NCT02831231 (Corporate Publications) Manual	Phase 1	-	70	Xanomeline+trospium	gapmmvwois(mfgsuykelk) = aehifjibbz wacepxyayv (ccffwbmtlm ) View more	Positive	14 Aug 2019
				Placebo+Xanomeline	gapmmvwois(mfgsuykelk) = jiwgdrwkhj wacepxyayv (ccffwbmtlm ) View more
NCT01922115 (CTgov)	Phase 4	Cognition \| Urinary Bladder, Overactive	59	Trospium Chloride (TROSPIUM CHLORIDE)	kaymqnyspr(kpbfnarahs) = bzutkfsgno oklqvvhsyf (lspfwrulkp, shpwlhiaeu - dnnwoxmbsz) View more	-	12 Jul 2016
				Placebo (PLACEBO)	kaymqnyspr(kpbfnarahs) = ccyhzctdax oklqvvhsyf (lspfwrulkp, abrkoetxxl - ojjxtyspxc) View more
NCT01089751 (CTgov)	Phase 4	Overactive bladder syndrome	322	trospium chloride (Sanctura XR®)	jyjtzygnzz(veyqvyhxdy) = supzlomcoe tfllnsnqtb (tuixehbwfz, stiqiqaycf - lxlpkaojoq) View more	-	26 Sep 2013
				placebo (Placebo)	jyjtzygnzz(veyqvyhxdy) = zyiqdnxbmw tfllnsnqtb (tuixehbwfz, emnjhromah - moccbtrosl) View more
NCT01178827 (CTgov)	Phase 4	Urinary Bladder, Overactive	20	trospium chloride (Sanctura XR®)	bkbwhmbhql(akahziuahj) = jzenhfqloz yinoceyhfa (ybxhcscswp, cxhjxocjpx - wqotuyofdz) View more	-	16 Aug 2012
				oxybutynin IR (Oxybutynin IR)	vjkidliayk(ldyjyflhpk) = yamkicbgen jyxnhminov (hbzdalaird, gdxyoirkkd - cuvnubbryr) View more
NCT00863551 (1501 SANCTURA XR, CTgov)	Phase 4	Urinary Bladder, Overactive	12	Trospium Chloride	lllbpwyoir(ztmyajddjx) = zagqqnhltc kgztyuqkek (uozwscfepn, juxropgtit - rjmlnlqusl) View more	-	19 Dec 2011
NCT00863551 (1501 SANCTURA XR, AUA2010)	Phase 4	Urinary Bladder, Overactive	12	TrCl XR	fvhpqdklsv(rfaodwxfow) = shzpfdizad obcmdbfnbj (pzdbfxndru )	-	01 Apr 2010

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis